EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs

High-grade serous ovarian cancer (HGSOC) is the most aggressive type of ovarian cancer and is responsible for most deaths caused by gynecological cancers. Numerous candidate biomarkers were identified for this disease in the last decades, but most were not sensitive or specific enough for clinical applications. Hence, new biomarkers for HGSOC are urgently required. This study aimed to identify new markers by isolating different extracellular vesicle (EV) types from the ascites of ovarian cancer patients according to their affinities for lipid-binding proteins and analyzing their protein cargo. This approach circumvents the low signal-to-noise ratio when using biological fluids for biomarker discovery and the issue of contamination by large non-EV complexes. We isolated and analyzed three distinct EV populations from the ascites of patients with ovarian cancer or cirrhosis and observed that Annexin V-binding EVs have higher levels of matrix metalloproteinase 9 in malignant compared to portal-hypertensive ascites. As this protein was not detected in other EV populations, this study validates our approach of using different EV types for optimal biomarker discovery. Furthermore, MMP9 in Annexin V-binding EVs could be a HGSOC biomarker with enhanced specificity, because its identification requires detection of two distinct components, that is, lipid and protein.

[1]  E. White,et al.  Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models , 2011, IUBMB life.

[2]  N. Ahmed,et al.  Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research , 2013, Front. Oncol..

[3]  D. Fishman,et al.  Proinvasive Properties of Ovarian Cancer Ascites-Derived Membrane Vesicles , 2004, Cancer Research.

[4]  R. Bast,et al.  Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. , 1996, Gynecologic oncology.

[5]  Yang Yang,et al.  A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis. , 2016, Lab on a chip.

[6]  Pauline M. Rudd,et al.  Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9) , 2002, Critical reviews in biochemistry and molecular biology.

[7]  A. Zilberberg,et al.  14‐3‐3 and β‐catenin are secreted on extracellular vesicles to activate the oncogenic Wnt pathway , 2014, Molecular oncology.

[8]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[9]  K. Schmetterer,et al.  Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer , 2016, Oncotarget.

[10]  Henrik J Johansson,et al.  Cells release subpopulations of exosomes with distinct molecular and biological properties , 2016, Scientific Reports.

[11]  S. Lim,et al.  Mesenchymal Stem Cell Exosomes: The Future MSC-Based Therapy? , 2013 .

[12]  C. Théry,et al.  Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation , 2012, Journal of extracellular vesicles.

[13]  C. Hess,et al.  Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils. , 2003, Experimental cell research.

[14]  Rochelle L. Garcia,et al.  Microparticles From Ovarian Carcinomas Are Shed Into Ascites and Promote Cell Migration , 2011, International Journal of Gynecologic Cancer.

[15]  S. Kaye,et al.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research , 2013, Nature Reviews Cancer.

[16]  Jian Cao,et al.  Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas , 2015, Genes & diseases.

[17]  E. Lengyel.  Ovarian cancer development and metastasis. , 2010, The American journal of pathology.

[18]  Cicek Gercel-Taylor,et al.  MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. , 2008, Gynecologic oncology.

[19]  Z. Fishelson,et al.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. , 2003, Molecular immunology.

[20]  D. Fishman,et al.  Production of extracellular matrix‐degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells , 1997, Cancer.

[21]  R. Hyatt,et al.  THE CIRCULATION OF ASCITIC FLUID : INTERCHANGE OF PLASMA AND ASCITIC FLUID PROTEIN AS STUDIED BY MEANS OF C14-LABELED LYSINE IN DOGS WITH CONSTRICTION OF THE VENA CAVA , 1950 .

[22]  G. Kristiansen,et al.  Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. , 2007, Gynecologic oncology.

[23]  A. Brisson,et al.  High-speed centrifugation induces aggregation of extracellular vesicles , 2015, Journal of extracellular vesicles.

[24]  A. Wong,et al.  Exosomes: Emerging biomarkers and targets for ovarian cancer. , 2015, Cancer letters.

[25]  Pier Giorgio Righetti,et al.  Proteome analysis in the clinical chemistry laboratory: myth or reality? , 2005, Clinica chimica acta; international journal of clinical chemistry.

[26]  D. Rockey,et al.  Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis , 1994, The Journal of cell biology.

[27]  S. Lim,et al.  MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA , 2016, Journal of extracellular vesicles.

[28]  K. Selvendiran,et al.  The biological significance and clinical applications of exosomes in ovarian cancer. , 2016, Gynecologic oncology.

[29]  R. Zeillinger,et al.  Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome , 2015, Oncotarget.

[30]  A. Villa,et al.  The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. , 2007, Cancer research.

[31]  S. Meri,et al.  Ascitic complement system in ovarian cancer , 2005, British Journal of Cancer.

[32]  Lynne T. Bemis,et al.  Standardization of sample collection, isolation and analysis methods in extracellular vesicle research , 2013, Journal of extracellular vesicles.

[33]  R. Agarwal,et al.  Mechanisms of transcoelomic metastasis in ovarian cancer. , 2006, The Lancet. Oncology.

[34]  Hakho Lee,et al.  Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor , 2014, Nature Biotechnology.

[35]  R. Nieuwland,et al.  Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation , 2014, Journal of extracellular vesicles.

[36]  R. Labianca,et al.  Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. , 2003, European journal of cancer.

[37]  S. Mornet,et al.  Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration , 2014, Journal of thrombosis and haemostasis : JTH.

[38]  Aled Clayton,et al.  Antigen‐presenting cell exosomes are protected from complement‐mediated lysis by expression of CD55 and CD59 , 2003, European journal of immunology.

[39]  K. Ekdahl,et al.  Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack , 2005, The Prostate.

[40]  Krisztina V. Vukman,et al.  Low-density lipoprotein mimics blood plasma-derived exosomes and microvesicles during isolation and detection , 2016, Scientific Reports.

[41]  S. Lim,et al.  Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles. , 2014, American journal of obstetrics and gynecology.

[42]  C. Théry,et al.  Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. , 2014, Annual review of cell and developmental biology.

[43]  S. Polterauer,et al.  Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread , 2016, Oncotarget.